T-cell regulation: With complements from innate immunity

Nature Reviews Immunology

Volumn 7, Issue 1, 2007, Pages 9-18

  Kemper, Claudia ^a   Atkinson, John P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; MANNAN BINDING LECTIN;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; APOPTOSIS; B LYMPHOCYTE ACTIVATION; BODY FLUID; CELL LINEAGE; CELL MIGRATION; COMPLEMENT SYSTEM; CYTOLYSIS; HUMAN; HUMORAL IMMUNITY; IMMUNE ADHERENCE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; OPSONIZATION; PATHOGENESIS; PHAGOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY, NATURAL; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 33845905781     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1994     Document Type: Review

References (105)

1. Medhzitov, R. & Janeway, C. A. Jr. Decoding the patterns of self and non-self by the innate immune system. Science 296, 298-300 (2002).
2. Walport, M. J. Complement. First of two parts. N. Engl. J. Med. 344, 1058-1066 (2001).
3. Walport, M. J. Complement. Second of two parts. N. Engl. J. Med. 344, 1140-1144 (2001).
4. Metschnikoff, E. Sur la lutte des cellule de l'organisme contre l'invasion des microbes. Ann. Inst. Pasteur 1, 321 (1887) (in French).
5. Bordet, J. & Gengou, O. Sur l'existence de substances sensibilisatrices dans la plupart des serum antimicrobien. Ann. Inst. Pasteur 15, 289-302 (1901) (in French).
6. Volanakis, J. E. in The Human Complement System in Health and Disease 10th edn (eds Volanakis, J. E. & Frank, M. M.) 9-32 (Marcel Dekker, New York, 1998).
7. Morgan, B. P. & Harris, C. L. Complement Regulatory Proteins (Academic, New York, 1999).
8. Kim, D. D. & Song, W.-C. Membrane complement regulatory proteins. Clin. Immunol. 118, 127-136 (2006).
9. Korb, L. C. & Ahearn, J. M. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J. Immunol. 158, 4525-4528 (1997).
10. Botto M. et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nature Genet. 19, 56-59 (1998).
11. Riley-Vargas, R. C., Lanzendorf, S. & Atkinson, J. P. Targeted and restricted complement activation on acrosome-reacted spermatozoa. J. Clin. Invest. 115, 1241-1249 (2005).
12. Harris, C. L., Mizuno, M. & Morgan, B. P. Complement and complement regulators in the male reproductive system. Mol. Immunol. 43, 57-67 (2006).
13. Nussenzweig, V., Bianco, C., Dukor, P. & Eden, A. in Progress in Immunology Vol. 59 (ed. Amos, B.) 73-81 (Academic, New York, 1971).
14. Carroll, M. C. The complement system in regulation of adaptive immunity. Nature Immunol. 10, 981-986 (2004).
15. Mastellos, D. & Lambris, J. D. Complement: more than a 'guard' against invading pathogens? Trends Immunol. 23, 485-491 (2002).
16. Nielsen, C. H., Fischer, E. M. & Leslie, R. G. The role of complement in the acquired immune response. Immunology 100, 4-12 (2000).
17. Pepys, M. B. Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J. Exp. Med. 140, 126-145 (1974).
18. Carter, R. H., Spycher, M. O., Ng, Y. C., Hoffman, R. & Fearon, D. T. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J. Immunol. 141, 457-467 (1988).
19. Dempsey, P. W., Allison, M. E., Akkaraju, S., Goodnow, C. C. & Fearon, D. T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271, 348-350 (1996).
20. Fearon, D. T. & Carter, R. H. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Ann. Rev. Immunol. 13, 127-149 (1995).
21. Fang, Y., Xu, C., Fu, Y., Holer, V. M. & Molina, H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J. Immunol. 160, 5273-5279 (1998).
22. Molina, H. et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl Acad. Sci. USA 93, 3357-3361 (1996).
23. Carroll, M. C. The complement system in B cell regulation. Mol. Immunol. 41, 141-146 (2004).
24. + cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421, 388-392 (2003). Provides evidence that a complement inhibitor influences T-cell responses through the generation of IL-10-producing regulatory T cells.
25. Morgan, B. P., Marchbank, K. J., Longhi M. P., Harris, C. L. & Gallimore, A. M. Complement: central to innate immunity and bridging to adaptive responses. Immunol. Lett. 97, 171-179 (2005).
26. Longhi, M. P., Harris, C. L., Morgan, B. P. & Gallimore, A. Holding T cell in check - a new role for complement regulators? Trends Immunol. 27, 102-108 (2006).
27. Hawlisch, H. & Köhl, J. Complement and Toll-like receptors: key regulators of adaptive immune responses. Mol. Immunol. 43, 13-21 (2006).
28. Köhl, J. et al. A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J. Clin. Invest. 116, 783-96 (2006).
29. Castellano, G. et al. Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood 103, 3813-3820 (2004).
30. Jiang, K., Chen, Y., Xu, C. S. & Jarvis, J. N. T cell activation by soluble C1q-bearing immune complexes: implications for the pathogenisis of rheumatoid arthritis. Clin. Exp. Immunol. 131, 61-67 (2003).
31. Jacquier-Sarlin, M. R., Gabert, F. M., Villiers, M. B. & Colomb, M. G. Modulation of antigen processing and presentation by covalently linked complement C3b fragment. Immunology 84, 164-170 (1995).
32. Kerekes, K. et al. Adjuvant effect of γ-inulin is mediated by C3 fragments deposited on antigen-presenting cells. J. Leuk. Biol. 69, 69-74 (2001).
33. Marth, T. & Kelsall, B. L. Regulation of interleukin-12 by complement receptor 3 signaling. J. Exp. Med. 185, 1987-1995 (1997).
34. Hawlisch, H., Wills-Karp, M., Karp, C. L. & Köhl, J. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol. Immunol. 41, 123-131 (2004).
35. Sozzani, S. et al. Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J. Immunol. 155, 3292-3295 (1995).
36. Wetsel, R. A. Structure, function and cellular expression of complement anaphylatoxin receptors. Curr. Opin. Immunol. 7, 48-53 (1995).
37. H2 effector functions in a murine model of pulmonary allergy. J. Immunol. 167, 4141-4145 (2001). This report, along with references 38-41 and 56, delineates the impact of the anaphylatoxins on T-cell lineage commitment during APC-T-cell interactions.
38. H2 functions in a murine model of pulmonary allergy. J. Immunol. 169, 5926-5933 (2002).
39. Gerard, N. P. & Gerard, C. Complement in allergy and asthma. Curr. Opin. Immunol. 14, 705-708 (2002).
40. H2 response to epicutaneously introduced antigen. J. Clin. Invest. 114, 399-407 (2004).
41. Hawlisch, H. et al. C5a negatively regulates Toll-like receptor 4-induced immune responses. Immunity 22, 15-425 (2005).
42. Källström, H., Islam, M. S., Berggren, P. O. & Jonsson, A. B. Cell signaling by the type IV pili of pathogenic Neisseria. J. Biol. Chem. 273, 21777-21782 (1998).
43. Karp, C. L. et al. Mechanisms of suppression of cell-mediated immunity by measles virus. Science 273, 228-231 (1996). Measles virus uses the immunomodulatory properties of a complement regulator to suppress the immune response.
44. Cattaneo, R. Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens' magnet. J. Virol. 78, 4385-4388 (2004).
45. Heeger, P. S. et al. Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 201, 1523-1530 (2005). Shows that complement components produced by APCs on antigen encounter modulate subsequent cytokine production by T cells.
46. Helmy, K. Y. et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124, 915-927 (2006).
47. Kang, Y.-S. et al. A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q. Cell 125, 47-58 (2006).
48. Wagner, C. & Hänsch, G. M. Receptors for complement C3 on T-lymphocytes: relics of evolution or functional molecules. Mol. Immunol. 43, 22-30 (2006).
49. Wilson, J. G., Tedder, T. F. & Fearon, D. T. Characterization of human T cells that express the C3b receptor. J. Immunol. 134, 684-689 (1983).
50. Wagner, C. The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes. Mol. Immunol. 43, 643-651 (2006).
51. Muto, S., Vetvicka, V. & Ross, G. D. CR3 (CD11b/CD18) expressed by cytotoxic T cells and natural killer cells is upregulated in a manner similar to neutrophil CR3 following stimulation with various activating agents. J. Clin. Immunol. 13, 175-184 (1993).
52. Eggleton, P., Tenner, A. J. & Reid, K. B. M. C1q receptors. Clin. Exp. Immunol. 120, 406-412 (2000).
53. Chen, A. et al. Human T cells express specific sites for C1q: role in T cell activation and proliferation. J. Immunol. 153, 1430-1440 (1994).
54. Nataf, S., Davoust, N., Ames, R. S. & Barnum, S. A. Human T cells express the C5a receptor and are chemoattracted to C5a. J. Immunol. 162, 4018-4023 (1999).
55. Tsuji, R. F. et al. Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J. Immunol. 165, 1588-1598 (2000).
56. Grant, E. P. et al. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J. Exp. Med. 196, 1461-1471 (2002).
57. Werfel, T. et al. Activated human T lymphocytes express a functional C3a receptor. J. Immunol. 165, 6599-6605 (2000).
58. CBL and LAT phosphorylation. J. Immunol. 164, 6091-6095 (2000). Establishes that signalling through CD46 modulates T-cell proliferation. This paper laid the ground work for the subsequent studies of the effects on T-cell function induced by CD46 crosslinking.
59. Reg cells synthesize granzyme A, whereas adaptive regulatory T cells produce granzyme B. On CD46 activation both cell types can kill activated, immunocompetent cells.
60. + T lymphocytes. Eur. J. Immunol. 34, 2439-2448 (2004).
61. Liu, J. et al. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J. Exp. Med. 201, 567-577 (2005). This report, together with reference 45, shows that complement deposition on APCs and T cells influences T-cell proliferation and cytokine production during APC-T-cell interactions.
62. Korty, P. E., Brando, C. & Shevach, E. M. CD59 functions as a signal-transducing molecule for human T cell activation. J. Immunol. 146, 4092-4098 (1991).
63. + T-cell responses to viral infections.
64. Suresh, M. et al. Complement component 3 is required for optimal expansion of CD8 T cells during a system viral infection. J. Immunol. 170, 788-794 (2003).
65. Verschoor, A., Brockman, M. A., Gadjeva, M., Knipe, D. M. & Carroll, M. C. Myeloid C3 determines induction of humoral responses to peripheral herpes simplex virus infection. J. Immunol. 171, 5363-5371 (2003).
66. + T cell responses. Nature Med. 9, 1287-1292 (2003).
67. Hopken, U. E., Lu, B., Gerard, N. P. & Gerard, C. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 383, 86-89 (1996).
68. + T cell responses. J. Immunol. 173, 2524-2529 (2004).
69. Karp, C. L. et al. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nature Immunol. 1, 221-226 (2000).
70. Wittman, M. et al. C5a suppresses the production of IL-12 by IFN-γ-primed and lipopolysaccharide-challenged human monocytes. J. Immunol. 162, 6763-6769 (1999).
71. Marie, J. C. et al. Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. Nature Immunol. 3, 659-666 (2002). This in vivo study supports a role for CD46 in the regulation of T-cell responses. The authors used mice transgenic for human CD46 to modulate T-cell responses in a contact-hypersensitivity model.
72. + T cell activity in a complement-independent manner. J. Immunol. 175, 7098-7102 (2005).
73. Riley-Vargas, R. C., Gill, D. B., Kemper, C., Liszewski, M. K. & Atkinson, J. P. CD46: expanding beyond complement regulation. Trends Immunol. 25, 496-503 (2004).
74. Kemper, C., Verbsky, J. W., Price, J. D. & Atkinson, J. P. T cell stimulation and regulation: with complements from CD46. Immunol. Res. 32, 31-43 (2005).
75. Foley, S., Li, B., Dehoff, M., Molina, M. & Holers, V. M. Mouse Crry/p65 is a regulator of the alternative pathway of complement activation. Euro. J. Immunol. 23, 1381-1384 (1993).
76. Fernandez-Centeno, E., de Ojeda, G., Rojo, J. M. & Portoles, P. Crry/p65, a membrane complement regulatory protein, has costimulatory properties on mouse T cells. J. Immunol. 164, 4533-4542 (2000).
77. Elward, et al. CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J. Biol. Chem. 280, 36342-36354 (2005). Shows that the expression profile of complement receptors and regulators can send inhibitory (or inducing) phagocytic signals. Proposes, together with reference 79, new roles for complement in the apoptotic process in addition to its function in the safe removal of dead cells.
78. Cole, D. S., Hughes, T. R., Gasque, P. & Morgan, B. P. Complement regulator loss on apoptotic neuronal cells causes increased complement activation and promotes both phagocytosis and cell lysis. Mol. Immunol. 43, 1953-1964 (2006).
79. Legembre, P. et al. Cutting edge: modulation of Fas-mediated apoptosis by lipid rafts in T lymphocytes. J. Immunol. 176, 716-720 (2006).
80. Grossmann, W. et al. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104, 2840-2848 (2004).
81. Bluestone, J. A. & Abbas, A. K. Natural versus adapative regulatory T cells. Nature Rev. Immunol. 3, 253-257 (2003).
82. Jonuleit, H. & Schmitt, E. The regulatory T cell family: distinct subsets and their interrelations. J. Immunol. 171, 6323-6327 (2003).
83. + T cells by streptococcal M protein. J. Immunol. 175, 677-684 (2005).
84. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737-742 (1997).
85. Asseman, C., Mauze, S., Leach, M. W., Coffman, R. L. & Powrie, F. An essential role for interleukin-10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190, 995-1004 (1997).
86. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J. Immunol. 174, 1783-1786 (2005).
87. + regulatory T cells in immunological tolerance to self and non-self. Nature Immunol. 6, 345-352 (2005).
88. H3 T cells by oral administration of myelin in multiple sclerosis patients. J. Clin. Invest. 98, 70-77 (1996).
89. O'Garra, A. & Vieira, P. Regulatory T cells and mechanisms of immune system control. Nature Med. 10, 801-805 (2004).
90. Barchet, W. et al. Complement-induced regulatory T cells suppress T cell responses but allow for dendritic cell activation. Blood 107, 1497-1504 (2006).
91. Cong, Y., Weaver, C. T., Lazenby, A. & Elson, C. O. Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to enteric flora. J. Immunol. 169, 6112-6119 (2002).
92. Kuhn, R., Lohler, J., Rennick, D., Rajewski, K. & Müller, W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263-274 (1993).
93. Sadlack, B. et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75, 253-261 (1993).
94. McGuirk, P., McCann, C. & Mills, K. H. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J. Exp. Med. 195, 221-231 (2002).
95. Lavelle, E. C. et al. Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. J. Immunol. 171, 2384-2392 (2003).
96. Russel, S. CD46: a complement regulator and pathogen receptor that mediates links between innate and acquired immune function. Tissue Antigens 64, 111-118 (2004).
97. Wang, G., Liszewski, M. K., Chan, A. C. & Atkinson, J. P. Membrane cofactor protein (MCP; CD46): isoform-specific tyrosine phosphorylation. J. Immunol. 164, 1839-1846 (2000).
98. Kurita-Taniguchi, M. et al. Functional modulation of human macrophages through CD46 (measles virus receptor): production of IL-12 p40 and nitric oxide in association with recruitment of protein-tyrosine phosphatase SHP-1 to CD46. J. Immunol. 165, 5143-5152 (2000).
99. Ludford-Menting, M. J. et al. A functional interaction between CD46 and DLG4: a role for DLG4 in epithelial polarization. J. Biol. Chem. 277, 4477-4484 (2002).
100. Zaffran, Y. et al. CD46/CD3 costimulation induces morphological changes of human T cells and activation of Vav, Rac, and extracellular signal-regulated kinase mitogen-activated protein kinase. J. Immunol. 167, 780-6785 (2001).
101. Davis, L. S., Patel, S. S., Atkinson, J. P. & Lipsky, P. E. Decay-accelerating factor functions as a signal transducing molecule for human T cells. J. Immunol. 141, 2246-2252 (1988).
102. Loertscher, R. & Lavery, P. The role of glycosyl phosphatidyl inositol (GPI)-anchored cell surface proteins in T-cell activation. Transpl. Immunol. 9, 93-96 (2002).
103. Pratt, J. R., Basher, S. A. & Sacks, S. H. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nature Med. 8, 582-587 (2002). Complement mediates graft rejection through mechanisms that include increases in proinflammatory cytokine secretion by vessel walls and the recruitment of effector T cells.
104. Sacks, S. H., Chowdhury, P. & Zhou, W. Role of the complement system in rejection. Curr. Opin. Immunol. 15, 487-492 (2003).
105. Makrides, S. C. Therapeutic inhibition of the complement system. Pharm. Rev. 50, 59-87 (1998).